Current trials: Marginal Zone Lymphoma12

The following clinical trials are currently offered in Germany in this group. More about Marginal Zone Lymphoma

12 matching trials

ARIADNERecruiting

An observational study of the already approved drug zanubrutinib in the treatment of various blood cancers, to gather more data on the tolerability and safety of the therapy

Zanubrutinib is an already approved drug that can be used to treat patients with Waldenström macroglobulinemia (WM), chronic lymphocytic leukemia (CLL), marginal zone lymphoma (MZL), or follicular lymphoma (FL). Since some of these conditions are very rare, there is not yet sufficient information on the use of this medication in clinical practice. The ARIADNE study is investigating how the treatment affects patients’ quality of life, including how often it requires inpatient care. Patients who are at least 18 years old and have one of the conditions listed above are eligible to participate in the study.

18 years and older · First line · Phase IV

BGB-16673-101Recruiting

New treatment approach (drug: BGB-16673) as an adjunct to standard therapy with BTK inhibitors for various B-cell lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. A new mechanism of action (drug: BGB-16673) does not inhibit BTK but instead targets its destruction. The goal of the CaDAnCe-101 study is to investigate the optimal dosage, safety, and efficacy of the drug BGB-16673. Patients aged 18 and older with a variety of different NHLs are eligible to participate in the study. There must be no involvement of the central nervous system (CNS).

18 years and older · Relapsed / refractory · Phase I/II

ELM-2Recruiting

A new antibody (Odronextamab) for the treatment of B-cell non-Hodgkin lymphomas in patients who have already received prior treatment

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system that can occur in various subtypes. Standard treatment often consists of immunochemotherapy; however, the disease may remain active (refractory) or become active again (recurrence). Odronextamab is a new antibody that targets cancer cells while simultaneously stimulating the immune system (bispecific). It is already approved for treatment in certain situations. The ELM-2 study is investigating the efficacy and safety of this new antibody (odronextamab). The study is open to women and men aged 18 and older who have follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or another subtype of B-cell NHL, and whose disease is either refractory or has relapsed.

18 years and older · Relapsed / refractory · Phase II

MK-1026-003Recruiting

New Drug (Nemtabrutinib) for the Treatment of Various B-Cell Non-Hodgkin Lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a so-called Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. BTK inhibitors specifically target the metabolism of cancer cells and inhibit their growth. This study is investigating the optimal dosage, safety, and efficacy of a new BTK inhibitor called nemtabrutinib (MK-1026). Women and men aged 18 and older with certain types of NHL are eligible to participate in this study, including chronic lymphocytic leukemia (CLL/SLL), Richter syndrome, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström macroglobulinemia (WM).

18 years and older · Relapsed / refractory · Phase II

GDL-ISRT 20 GyRecruiting

Lower Radiation Dose for Radiation Therapy of Marginal Zone Lymphoma and Follicular Lymphoma Involving the Gastrointestinal Tract

Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are malignant diseases of the lymphatic system that can also occur in the gastrointestinal tract. If the disease is localized, radiation therapy is used as a treatment. The goal of the GDL-ISRT 20 Gy study is to investigate whether a lower radiation dose than the current standard (30 Gy) is effective and safe and may be associated with fewer (long-term) side effects. Patients aged 18 and older with MZL or FL in the stomach or duodenum are eligible to participate in the study.

18 years and older · First line · Phase II

17-BI-1206-02In preparation

Can a new drug enhance the effectiveness of rituximab—a standard treatment for non-Hodgkin lymphoma—if the disease becomes active again?

B-cell non-Hodgkin lymphomas (NHL) are a group of malignant blood cancers. The antibody rituximab is a commonly used drug for these diseases; however, treatment is not always effective (refractory), or a relapse (recurrence) may occur. The aim of this study is to investigate the tolerability and efficacy of the new drug BI-1206, an antibody, in combination with rituximab. Among other things, it is hypothesized that BI-1206 enhances the effect of rituximab. Men and women with so-called indolent NHL are eligible to participate: follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL), who are at least 18 years old and have already received at least one line of treatment that included rituximab.

18 years and older · Relapsed / refractory · Phase I/II

RUBINRecruiting

An observational study to collect treatment data for the long-term optimization of treatment in non-Hodgkin B-cell lymphomas

B-cell lymphomas are malignant diseases of the lymphatic system. To further improve treatment, it is important to collect treatment data in a structured manner over the long term. The goal of the RUBIN study is to collect data on treatment, quality of life, and disease progression in patients with these conditions. Patients aged 18 and older with B-cell lymphomas are eligible to participate in this study. The study does not test new medications or forms of therapy.

18 years and older · Phase IV

PRT2527-02In preparation

A study of the drug "PRT2527" alone and in combination with zanubrutinib in various refractory and relapsed hematologic diseases

Malignant diseases of the blood and lymphatic system are usually treated with immunochemotherapy. These treatments are often effective. If the disease cannot be controlled by this approach (refractory) or if disease activity resumes (recurrence), the therapy must be intensified. The aim of this study is to investigate the safety and efficacy of the drug “PRT2527” as monotherapy and in combination with the approved drug zanubrutinib. Patients aged 18 and older with aggressive B-cell lymphoma, mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter transformation, or T-cell lymphoma (TCL) are eligible to participate in this study.

18 years and older · Relapsed / refractory · Phase I

M23-647Recruiting

New Drug Candidate (ABBV-101) for the Treatment of Previously Treated B-Cell Lymphomas

Established treatments are available for B-cell lymphomas, a form of blood cancer. To improve treatment options, new drugs continue to be studied. A new active ingredient (ABBV-101) specifically targets the metabolism of malignant cells. The goal of the study is to evaluate ABBV-101 to determine the optimal dose and efficacy for lymphomas. The study is open to men and women aged 18 and older who have B-cell lymphoma and have already undergone at least three lines of treatment.

18 years and older · Relapsed / refractory · Phase I

OLYMPIA-5Recruiting

The bispecific antibody Odronextamab is already approved for follicular lymphoma (FL)—Does the combination with lenalidomide provide additional benefit in patients with previously treated FL or marginal zone lymphoma?

B-cell lymphomas, such as follicular lymphoma (FL) and marginal zone lymphoma (MZL), are types of non-Hodgkin lymphoma and are malignant diseases of the lymphatic system. Odronextamab is a bispecific antibody that binds simultaneously to cancer cells and immune cells, thereby triggering a targeted immune response against the tumor cells. Odronextamab is already approved for FL. Its efficacy in combination with lenalidomide, another approved drug, has not yet been studied. The goal of the OLYMPIA-5 study is to compare the efficacy and safety of odronextamab in combination with lenalidomide to the current standard of care (rituximab + lenalidomide). Patients aged 18 and older with FL or MZL who have experienced a recurrence of the disease after prior therapy or whose disease has not responded to prior therapy (refractory) are eligible to participate.

18 years and older · Relapsed / refractory · Phase III